Abstract # | |||||
---|---|---|---|---|---|
51 | 54 | 4053 | 942 | 1414 | |
Authors (references) | Goekbuget et al. [4] | Hatta et al. [5] | Shimony et al. [6] | Suo et al. [11] | Yu et al. [12] |
Study agents | Nelarabine + cyclophosphamide | Nelarabine + L-ASP | Nelarabine monotherapy vs combination | Venetoclax + HAG | Venetoclax + HAG |
Analysis | N/A | II | Retrospective | N/A | II |
NCT No | NCT02881086 | N/A | N/A | N/A | N/A |
Study period | N/A | 2011–2017 | 2006–2021 | N/A | 2021–2022 |
Age range, years | 18–55 | 15–24 | 2–69 | N/A | 15–60 |
No. of patients | 281 (208 T-ALL; 73 T-LBL) | 62 | 44 (29 combination; 15 monotherapy) | 7 (3 R/R ETP-ALL; 4 newly diagnosed) | 7 |
MRD analysis used to assign risk/postremission therapy | Yes | Yes (< 10–3) | Yes | No | Yes (< 0.01%) |
Outcome measure | 1-year OS, 3-year OS, OS for SCT | 3-year EFS, 3-year OS, 3-year CIR | CR, RFS, OS | CR/CRi rate | CR/CRi rate |
Survival outcome | 1-year OS: 89%; 3-year OS: 78% | 3-year EFS: 88.6%; 3-year OS: 93.4%; 3-year CIR: 5.3% | CR: 55%; 2-year RFS: 60.5%; 2-year OS: 37.6% | CR/CRi rate: 100% | CR/CRi rate(after the first cycle): 85.7%; CR: 42.9%; CRi: 42.9%; PR: 14.3%; CR/CRi rate(after the second cycle): 100% |
Summary | Early T-ALL subgroup appeared poorer outcomes | Risk stratification system in pediatric regimen was also effective for AYA patients | Nelarabine combination regimen led to better outcomes than monotherapy | V-HAG regimen in newly diagnosed and R/R ETP-ALL has led to favorable outcomes | VGHA regimen provides a new choice in the treatment of R/R ETP-ALL patients |